Your browser doesn't support javascript.
loading
Persistent serological activity in primary Sjögren's syndrome.
López-Morales, Jorge; Cortes-Muñoz, Daniel; Astudillo-Ángel, Miguel; Hernández-Molina, Gabriela.
Afiliação
  • López-Morales J; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Immunology and Rheumatology, Vasco de Quiroga 15. Col. Belisario Domínguez Sección XVI. CP, 14080, Mexico City, Mexico.
  • Cortes-Muñoz D; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Immunology and Rheumatology, Vasco de Quiroga 15. Col. Belisario Domínguez Sección XVI. CP, 14080, Mexico City, Mexico.
  • Astudillo-Ángel M; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Immunology and Rheumatology, Vasco de Quiroga 15. Col. Belisario Domínguez Sección XVI. CP, 14080, Mexico City, Mexico.
  • Hernández-Molina G; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Immunology and Rheumatology, Vasco de Quiroga 15. Col. Belisario Domínguez Sección XVI. CP, 14080, Mexico City, Mexico. gabyhm@yahoo.com.
Clin Rheumatol ; 39(3): 919-923, 2020 Mar.
Article em En | MEDLINE | ID: mdl-31838639
To assess the presence of persistent serological activity and its association with clinical outcomes in primary Sjögren's syndrome. Clinical charts of 275 patients were reviewed retrospectively. Persistent serological activity was defined as an increase IgG ≥ 1.6 mg/dL or globulins > 3.7 g/dL or diminished C3 < 52 mg/dL or C4 < 12 mg/dL at least during two consecutive visits during a year (index period). The ClinESSDAI at the index period and the cumulative ClinESSDAI and the SSDDI at the last medical appointment were scored. A total of 159 patients with complete serological data were included mostly women and median disease duration of 10.2 years. Persistent serological activity was identified in 85 patients (53.1%). Only 13 patients changed their status to serological inactivity though the follow-up. Comparison of patients with (n = 85) versus without persistent serological activity (n = 74) showed that the first group had a higher frequency of impaired non-stimulated salivary flow, anti-La/SSB antibody, and RF, as well as higher ClinESSDAI scores. The most affected domains were the constitutional, glandular, cutaneous, renal, and hematological domains. On logistic regression analysis, the RF (OR 6.4, 95% CI 1.8-22, p = 0.003), the renal (OR 12.8, 95% CI 1.7-92, p = 0.01), and the hematological involvement (OR 4.7, 95% CI 1.6-13.4, p = 0.004) remained associated. Half of the patients studied had persistent serological activity, being this status constant through the follow-up. Persistent serological activity was associated with positive RF and higher ESSDAI scores due to hematological and renal activity. Scoring serological activity is an important issue in SS patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Índice de Gravidade de Doença / Síndrome de Sjogren / Anticorpos Antinucleares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Rheumatol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: México País de publicação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Índice de Gravidade de Doença / Síndrome de Sjogren / Anticorpos Antinucleares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Rheumatol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: México País de publicação: Alemanha